Compare
Protalix BioTherapeutics, Inc. vs Invivyd, Inc. vs Champions Oncology, Inc. vs Vir Biotechnology, Inc.
| Latest fiscal year | Protalix BioTherapeutics, Inc. PLX | Invivyd, Inc. IVVD | Champions Oncology, Inc. CSBR | Vir Biotechnology, Inc. VIR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-04-30 | 2025-12-31 |
| Revenue | $52.74M | $53.43M | $59.42M | $68.56M |
| Revenue growth (YoY) | -1.2% | +110.5% | +4.4% | -7.6% |
| Gross margin | 48.8% (computed) | n/a | 48.0% (computed) | n/a |
| Operating margin | -10.4% | -104.0% | -1.9% | -699.2% |
| Net margin | -12.5% | -98.2% | -2.0% | -638.9% |
| Net income | -$6.60M | -$52.49M | -$1.18M | -$437.99M |
| EPS (Diluted) | -$0.08 | -$0.30 | -$0.08 | -$3.16 |
| Operating cash flow | -$11.99M | -$58.13M | -$4.47M | -$391.78M |
| Free cash flow | -$13.63M | -$58.29M | -$5.04M | -$396.61M |
| Cash & equivalents | $14.68M | $226.69M | n/a | $232.19M |
| Total assets | $82.35M | $276.88M | $26.99M | $1.00B |
| Total liabilities | $34.12M | $35.34M | $22.92M | $237.55M |
| Shareholders' equity | $48.23M | $241.54M | $3.94M | $765.28M |
| Return on year-end equity | -13.7% | -21.7% | -29.8% | -57.2% |
| Shares outstanding | 80.43M | 281.99M | 13.89M | 139.47M |
Revenue, most recent five fiscal years
| Fiscal year | Protalix BioTherapeutics, Inc. | Invivyd, Inc. | Champions Oncology, Inc. | Vir Biotechnology, Inc. |
|---|---|---|---|---|
| Latest | $52.74M Ended 2025-12-31 | $53.43M Ended 2025-12-31 | $59.42M Ended 2026-04-30 | $68.56M Ended 2025-12-31 |
| 1 year earlier | $53.40M Ended 2024-12-31 | $25.38M Ended 2024-12-31 | $56.94M Ended 2025-04-30 | $74.20M Ended 2024-12-31 |
| 2 years earlier | $65.49M Ended 2023-12-31 | $0 Ended 2023-12-31 | $50.16M Ended 2024-04-30 | $86.18M Ended 2023-12-31 |
| 3 years earlier | $47.64M Ended 2022-12-31 | n/a | $53.87M Ended 2023-04-30 | $1.62B Ended 2022-12-31 |
| 4 years earlier | $38.35M Ended 2021-12-31 | n/a | $49.11M Ended 2022-04-30 | $1.10B Ended 2021-12-31 |